- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 261/14 - Nitrogen atoms
Patent holdings for IPC class C07D 261/14
Total number of patents in this class: 273
10-year publication summary
|
35
|
22
|
11
|
15
|
11
|
10
|
14
|
11
|
12
|
4
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Amira Pharmaceuticals, Inc. | 70 |
20 |
| Boehringer Ingelheim International GmbH | 4650 |
16 |
| Bristol-myers Squibb Company | 4898 |
9 |
| Cytokinetics, Inc. | 277 |
8 |
| Epigen Biosciences, Inc. | 13 |
8 |
| Centrexion Therapeutics Corporation | 65 |
7 |
| Vectus Biosystems Limited | 35 |
7 |
| Autobahn Therapeutics, Inc. | 43 |
7 |
| Takeda Pharmaceutical Company Limited | 2713 |
5 |
| Oryzon Genomics S.A. | 106 |
5 |
| Proteostasis Therapeutics, Inc. | 70 |
5 |
| Novartis AG | 10849 |
4 |
| BASF SE | 20933 |
4 |
| Boehringer Ingelheim Pharma GmbH & Co. Kg | 570 |
4 |
| Chiesi Farmaceutici S.p.A. | 969 |
4 |
| Plexxikon Inc. | 150 |
4 |
| Romark Laboratories L.C. | 52 |
4 |
| Merck Sharp & Dohme LLC | 3748 |
4 |
| Syngenta Participations AG | 1903 |
3 |
| Board of Regents, The University of Texas System | 5793 |
3 |
| Other owners | 142 |